Trial of RAD001 in Triple Negative Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The hypothesis of this clinical research study is to discover if the study drug RAD001 can
shrink or slow the growth of Estrogen Receptor/Progesterone Receptor (ER/PR) negative or
Human Epidermal growth factor Receptor 2 (Her2 Neu) negative breast cancer. The safety of
RAD001 will also be studied. Patients physical state, symptoms, changes in the size of the
tumor, and laboratory findings obtained while on-study will help the research team decide if
RAD001 is safe and effective.